{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:45Z","timestamp":1792784985056,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the Friedrich-Alexander-Universit\u00e4t of Erlangen-N\u00fcrnberg","award":["Advanced Projects A101"],"award-info":[{"award-number":["Advanced Projects A101"]}]},{"name":"Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the Friedrich-Alexander-Universit\u00e4t of Erlangen-N\u00fcrnberg","award":["Advanced Projects A101"],"award-info":[{"award-number":["Advanced Projects A101"]}]},{"name":"Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the Friedrich-Alexander-Universit\u00e4t of Erlangen-N\u00fcrnberg","award":["Advanced Projects A101"],"award-info":[{"award-number":["Advanced Projects A101"]}]},{"name":"Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the Friedrich-Alexander-Universit\u00e4t of Erlangen-N\u00fcrnberg","award":["Advanced Projects A101"],"award-info":[{"award-number":["Advanced Projects A101"]}]},{"name":"European infrastrucal ISIDORe project","award":["ISID_8a6e"],"award-info":[{"award-number":["ISID_8a6e"]}]},{"name":"the BMBF","award":["SenseCoV2 01KI20172A"],"award-info":[{"award-number":["SenseCoV2 01KI20172A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mucosal immunity may be required to prevent the ongoing transmission of SARS-CoV-2 emerging variants of concern. To define the most efficient way to induce protective mucosal immunity, we compared three different forms of mucosal antigen exposure in mRNA pre-immunized rhesus macaques. Two vaccine groups received an oropharyngeal spray immunization with either an adenoviral vector or a live-attenuated SARS-CoV-2 vaccine (LAV). A third group was infected with SARS-CoV-2 Delta variant as a comparator group representing the exposure history of most humans. Profound levels of SARS-CoV-2-specific IgA antibodies and mucosal T cell responses in the bronchoalveolar lavage next to systemic IgG antibodies were induced after the adenoviral vector boost and the delta infection, but not after LAV immunization. Consequently, these two groups were better protected against a challenge infection with an immune-escape variant of the Omicron lineage EG.5.1.1 showing almost no upper and lower respiratory tract infection. The adenoviral vector vaccine would be a promising candidate for booster vaccinations to interrupt ongoing viral transmission and could generate similar levels of protection as a natural encounter with heterologous SARS-CoV-2.<\/jats:p>","DOI":"10.1038\/s41541-025-01307-6","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T10:15:01Z","timestamp":1765620901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adenoviral vector oropharyngeal spray immunization elicits mucosal immunity and protects against heterologous SARS-CoV-2 infection"],"prefix":"10.1038","volume":"10","author":[{"given":"Gerrit","family":"Koopman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Mooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roja Fidel","family":"Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Irrgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne","family":"Blankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Fagrouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga P.","family":"B\u00f6sz\u00f6rm\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond J.","family":"Remarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy M.","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst J.","family":"Verschoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gramberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Tenbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"1307_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N. Engl. J. Med. 386, 340\u2013350 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1307_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35815-7","volume":"14","author":"HF Tseng","year":"2023","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat. Commun. 14, 189 (2023).","journal-title":"Nat. Commun."},{"key":"1307_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","volume":"27","author":"T Kustin","year":"2021","unstructured":"Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 27, 1379\u20131384 (2021).","journal-title":"Nat. Med."},{"key":"1307_CR4","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1056\/NEJMc2302462","volume":"388","author":"DY Lin","year":"2023","unstructured":"Lin, D. Y. et al. Durability of bivalent boosters against Omicron subvariants. N. Engl. J. Med. 388, 1818\u20131820 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1307_CR5","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1128\/JVI.02736-13","volume":"88","author":"T Grunwald","year":"2014","unstructured":"Grunwald, T. et al. Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates. J. Virol. 88, 3997\u20134007 (2014).","journal-title":"J. Virol."},{"key":"1307_CR6","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.vaccine.2018.02.075","volume":"36","author":"D Lapuente","year":"2018","unstructured":"Lapuente, D., Ruzsics, Z., Thirion, C. & Tenbusch, M. Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Vaccine 36, 2712\u20132720 (2018).","journal-title":"Vaccine"},{"key":"1307_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/infdis\/jiae447","volume":"231","author":"N Pisanic","year":"2025","unstructured":"Pisanic, N. et al. Early, robust mucosal secretory immunoglobulin A but not immunoglobulin G response to severe acute respiratory syndrome Coronavirus 2 spike in oral fluid is associated with faster viral clearance and Coronavirus Disease 2019 symptom resolution. J. Infect. Dis. 231, 121\u2013130 (2025).","journal-title":"J. Infect. Dis."},{"key":"1307_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41590-024-01743-x","volume":"25","author":"B Ying","year":"2024","unstructured":"Ying, B. et al. Mucosal vaccine-induced cross-reactive CD8(+) T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection. Nat. Immunol. 25, 537\u2013551 (2024).","journal-title":"Nat. Immunol."},{"key":"1307_CR9","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMc2209651","volume":"387","author":"S Havervall","year":"2022","unstructured":"Havervall, S. et al. Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection. N. Engl. J. Med. 387, 1333\u20131336 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1307_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1473-3099(22)00834-9","volume":"23","author":"U Marking","year":"2023","unstructured":"Marking, U. et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect. Dis. 23, 150\u2013152 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1307_CR11","doi-asserted-by":"publisher","first-page":"eadd4853","DOI":"10.1126\/sciimmunol.add4853","volume":"7","author":"J Tang","year":"2022","unstructured":"Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 7, eadd4853 (2022).","journal-title":"Sci Immunol."},{"key":"1307_CR12","first-page":"e55","volume":"387","author":"F Zuo","year":"2022","unstructured":"Zuo, F., Marcotte, H., Hammarstrom, L. & Pan-Hammarstrom, Q. Mucosal IgA against SARS-CoV-2 Omicron infection. N. Engl. J. Med. 387, e55 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1307_CR13","doi-asserted-by":"publisher","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","volume":"36","author":"TL Bricker","year":"2021","unstructured":"Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021).","journal-title":"Cell Rep."},{"key":"1307_CR14","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","volume":"2","author":"AO Hassan","year":"2021","unstructured":"Hassan, A. O. et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep. Med. 2, 100230 (2021).","journal-title":"Cell Rep. Med."},{"key":"1307_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e113 (2020).","journal-title":"Cell"},{"key":"1307_CR16","doi-asserted-by":"publisher","first-page":"eabn6868","DOI":"10.1126\/scitranslmed.abn6868","volume":"14","author":"SN Langel","year":"2022","unstructured":"Langel, S. N. et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci Transl Med 14, eabn6868 (2022).","journal-title":"Sci Transl Med"},{"key":"1307_CR17","doi-asserted-by":"publisher","first-page":"eabo2523","DOI":"10.1126\/science.abo2523","volume":"378","author":"T Mao","year":"2022","unstructured":"Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).","journal-title":"Science"},{"key":"1307_CR18","doi-asserted-by":"crossref","unstructured":"Sun, B. et al. An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA. JCI Insight 9, (2024).","DOI":"10.1172\/jci.insight.180784"},{"key":"1307_CR19","doi-asserted-by":"publisher","first-page":"eadh1655","DOI":"10.1126\/sciadv.adh1655","volume":"2023","author":"G Baldeon Vaca","year":"2023","unstructured":"Baldeon Vaca, G. et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci Adv. 2023, eadh1655 (2023).","journal-title":"Sci Adv."},{"key":"1307_CR20","doi-asserted-by":"publisher","first-page":"104298","DOI":"10.1016\/j.ebiom.2022.104298","volume":"85","author":"M Madhavan","year":"2022","unstructured":"Madhavan, M. et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. eBioMedicine 85, 104298 (2022).","journal-title":"eBioMedicine"},{"key":"1307_CR21","doi-asserted-by":"publisher","first-page":"pgac091","DOI":"10.1093\/pnasnexus\/pgac091","volume":"1","author":"Y Sui","year":"2022","unstructured":"Sui, Y. et al. An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. PNAS Nexus. 1, pgac091 (2022).","journal-title":"PNAS Nexus."},{"key":"1307_CR22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect. Dis. 21, 1654\u20131664 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1307_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27063-4","volume":"12","author":"D Lapuente","year":"2021","unstructured":"Lapuente, D. et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat. Commun. 12, 6871 (2021).","journal-title":"Nat. Commun."},{"key":"1307_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-023-06951-3","volume":"626","author":"K McMahan","year":"2024","unstructured":"McMahan, K. et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature 626, 385\u2013391 (2024).","journal-title":"Nature"},{"key":"1307_CR25","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41590-024-01951-5","volume":"25","author":"M Gagne","year":"2024","unstructured":"Gagne, M. et al. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nat. Immunol. 25, 1913\u20131927 (2024).","journal-title":"Nat. Immunol."},{"key":"1307_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45348-2","volume":"15","author":"JM Adler","year":"2024","unstructured":"Adler, J. M. et al. An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission. Nat. Commun. 15, 995 (2024).","journal-title":"Nat. Commun."},{"key":"1307_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41423-022-00855-4","volume":"19","author":"ZW Ye","year":"2022","unstructured":"Ye, Z. W. et al. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. Cell Mol. Immunol. 19, 588\u2013601 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"1307_CR28","doi-asserted-by":"publisher","first-page":"eabl9105","DOI":"10.1126\/sciimmunol.abl9105","volume":"6","author":"MML Poon","year":"2021","unstructured":"Poon, M. M. L. et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. 6, eabl9105 (2021).","journal-title":"Sci. Immunol."},{"key":"1307_CR29","doi-asserted-by":"publisher","first-page":"e55648","DOI":"10.15252\/embr.202255648","volume":"23","author":"A Russ","year":"2022","unstructured":"Russ, A. et al. Nsp16 shields SARS-CoV-2 from efficient MDA5 sensing and IFIT1-mediated restriction. EMBO Rep. 23, e55648 (2022).","journal-title":"EMBO Rep."},{"key":"1307_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R Wolfel","year":"2020","unstructured":"Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"1307_CR31","doi-asserted-by":"publisher","first-page":"105662","DOI":"10.1016\/j.ebiom.2025.105662","volume":"114","author":"ZW Ye","year":"2025","unstructured":"Ye, Z. W. et al. A live attenuated SARS-CoV-2 vaccine constructed by dual inactivation of NSP16 and ORF3a. eBioMedicine 114, 105662 (2025).","journal-title":"eBioMedicine"},{"key":"1307_CR32","doi-asserted-by":"publisher","first-page":"857440","DOI":"10.3389\/fimmu.2022.857440","volume":"13","author":"A Volkmann","year":"2022","unstructured":"Volkmann, A. et al. A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects Rhesus Macaques. Front. Immunol. 13, 857440 (2022).","journal-title":"Front. Immunol."},{"key":"1307_CR33","doi-asserted-by":"publisher","first-page":"845887","DOI":"10.3389\/fimmu.2022.845887","volume":"13","author":"P Mooij","year":"2022","unstructured":"Mooij, P. et al. Poxvirus MVA expressing SARS-CoV-2 S protein induces robust immunity and protects Rhesus Macaques from SARS-CoV-2. Front. Immunol. 13, 845887 (2022).","journal-title":"Front. Immunol."},{"key":"1307_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","volume":"23","author":"N Bobrovitz","year":"2023","unstructured":"Bobrovitz, N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556\u2013567 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1307_CR35","doi-asserted-by":"publisher","first-page":"1145652","DOI":"10.3389\/fimmu.2023.1145652","volume":"14","author":"M Buscot","year":"2023","unstructured":"Buscot, M. et al. Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses. Front. Immunol. 14, 1145652 (2023).","journal-title":"Front. Immunol."},{"key":"1307_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1126\/science.adc9127","volume":"378","author":"YJ Park","year":"2022","unstructured":"Park, Y. J. et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 378, 619\u2013627 (2022).","journal-title":"Science"},{"key":"1307_CR37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","volume":"588","author":"Z Ke","year":"2020","unstructured":"Ke, Z. et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498\u2013502 (2020).","journal-title":"Nature"},{"key":"1307_CR38","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","volume":"71","author":"NJ Carter","year":"2011","unstructured":"Carter, N. J. & Curran, M. P. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71, 1591\u20131622 (2011).","journal-title":"Drugs"},{"key":"1307_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58931-y","volume":"16","author":"A Schmidt","year":"2025","unstructured":"Schmidt, A. et al. Inflammatory conditions shape phenotypic and functional characteristics of lung-resident memory T cells in mice. Nat. Commun. 16, 3612 (2025).","journal-title":"Nat. Commun."},{"key":"1307_CR40","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2024.02.017","volume":"57","author":"TS Johnston","year":"2024","unstructured":"Johnston, T. S. et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity 57, 912\u2013925 e914 (2024).","journal-title":"Immunity"},{"key":"1307_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47451-w","volume":"15","author":"J Pusnik","year":"2024","unstructured":"Pusnik, J. et al. Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin. Nat. Commun. 15, 3102 (2024).","journal-title":"Nat. Commun."},{"key":"1307_CR42","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.chom.2023.05.004","volume":"31","author":"MG Netea","year":"2023","unstructured":"Netea, M. G. et al. The role of trained immunity in COVID-19: Lessons for the next pandemic. Cell Host Microbe 31, 890\u2013901 (2023).","journal-title":"Cell Host Microbe"},{"key":"1307_CR43","doi-asserted-by":"publisher","first-page":"100520","DOI":"10.1016\/j.xcrm.2022.100520","volume":"3","author":"H Ishii","year":"2022","unstructured":"Ishii, H. et al. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8(+) T cell responses. Cell Rep. Med. 3, 100520 (2022).","journal-title":"Cell Rep. Med."},{"key":"1307_CR44","doi-asserted-by":"publisher","unstructured":"Karl, V., Hofmann, M. & Thimme, R. Role of antiviral CD8+T cell immunity to SARS-CoV-2 infection and vaccination. J. Virol. e0135024 https:\/\/doi.org\/10.1128\/jvi.01350-24 (2025).","DOI":"10.1128\/jvi.01350-24"},{"key":"1307_CR45","doi-asserted-by":"publisher","first-page":"eabq7647","DOI":"10.1126\/sciimmunol.abq7647","volume":"2022","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. Sci. Immunol. 2022, eabq7647 (2022).","journal-title":"Sci. Immunol."},{"key":"1307_CR46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"1307_CR47","doi-asserted-by":"publisher","first-page":"101828","DOI":"10.1016\/j.smim.2023.101828","volume":"70","author":"MO Diniz","year":"2023","unstructured":"Diniz, M. O., Maini, M. K. & Swadling, L. T cell control of SARS-CoV-2: When, which, and where? Semin. Immunol. 70, 101828 (2023).","journal-title":"Semin. Immunol."},{"key":"1307_CR48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41590-024-02072-9","volume":"26","author":"A Zhu","year":"2025","unstructured":"Zhu, A. et al. Robust mucosal SARS-CoV-2-specific T cells effectively combat COVID-19 and establish polyfunctional resident memory in patient lungs. Nat. Immunol. 26, 459\u2013472 (2025).","journal-title":"Nat. Immunol."},{"key":"1307_CR49","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s41590-021-01021-0","volume":"22","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat. Immunol. 22, 1306\u20131315 (2021).","journal-title":"Nat. Immunol."},{"key":"1307_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"1307_CR51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0169-328X(96)00085-X","volume":"41","author":"AJ Holtmaat","year":"1996","unstructured":"Holtmaat, A. J. et al. Efficient adenoviral vector-directed expression of a foreign gene to neurons and sustentacular cells in the mouse olfactory neuroepithelium. Brain Res. Mol. Brain Res. 41, 148\u2013156 (1996).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"1307_CR52","doi-asserted-by":"publisher","first-page":"13180","DOI":"10.1128\/JVI.01400-07","volume":"81","author":"C Stahl-Hennig","year":"2007","unstructured":"Stahl-Hennig, C. et al. Atraumatic oral spray immunization with replication-deficient viral vector vaccines. J. Virol. 81, 13180\u201313190 (2007).","journal-title":"J. Virol."},{"key":"1307_CR53","first-page":"389","volume":"60","author":"DL Brining","year":"2010","unstructured":"Brining, D. L. et al. Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis). Comp. Med. 60, 389\u2013395 (2010).","journal-title":"Comp. Med."},{"key":"1307_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22958-8","volume":"12","author":"S Dispinseri","year":"2021","unstructured":"Dispinseri, S. et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 12, 2670 (2021).","journal-title":"Nat. Commun."},{"key":"1307_CR55","doi-asserted-by":"publisher","first-page":"e20201181","DOI":"10.1084\/jem.20201181","volume":"217","author":"F Schmidt","year":"2020","unstructured":"Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).","journal-title":"J. Exp. Med."},{"key":"1307_CR56","doi-asserted-by":"crossref","unstructured":"Zelterman, D. John Wiley & Sons. Discrete Distributions: Applications in the Health Sciences Vol. 207 (Johan Wiley & Sons, 2004).","DOI":"10.1002\/0470868902"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01307-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:02:25Z","timestamp":1766584945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01307-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1307"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01307-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}